Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

Personalized Pharmacokinetic-Pharmacodynamic Guided Therapy via an Induced Pluripotent Stem Cell-Derived Multi-Organoid Platform in NF1-Mutant Breast Cancer

March 11, 2026

[Signal Transduction and Targeted Therapy] Investigators presented a personalized treatment model using a patient-derived Networking Organoid Culture System composed of intestinal, liver, and kidney organoids differentiated from iPSCs of an NF1-mutant breast cancer patient.

UH Researcher Joins $3.2 Million Effort to Develop Promising New Breast Cancer Treatment

March 5, 2026

[University of Houston] A University of Houston College of Pharmacy researcher has joined a $3.2 million effort to develop a promising new treatment for triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease, accounting for 10-15% of all breast cancer cases.

FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer

March 5, 2026

[Genentech] Genentech announced that the US FDA has accepted the company’s New Drug Application for giredestrant in combination with everolimus for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence or progression on a prior endocrine-based regimen.

Homologous Recombination Deficiency and Hemizygosity Drive Resistance in Breast Cancer

March 5, 2026

[Nature] Researchers found that germinline BRCA2-associated tumors are uniquely predisposed to develop acquired RB1 loss-of-function alterations, resulting in poor outcomes on standard-of-care frontline CDK4/6 inhibitor combinations.

OTUD4 Deubiquitination Stabilizes EGFR and Activates the PI3K/AKT Pathway to Promote the Invasiveness of Triple-Negative Breast Cancer

March 5, 2026

[Cell Death & Disease] Through bioinformatics analysis and experimental validation, investigators demonstrated that OTUD4 is overexpressed in TNBC and correlates with poor prognosis.

An AIB1 Isoform Rewires Glucocorticoid Receptor Signaling to Promote TNBC Progression

March 5, 2026

[Iscience] Researchers described a glucocorticoid receptor-dependent mechanism driving TNBC invasion, mediated by the presence of a subpopulation of cancer cells that express an N-terminal truncated splice isoform of the nuclear receptor coactivator AIB1.

Functional Effects of EpCAM N-Glycosylation in MDA-MB-468 Breast Cancer Cells

March 5, 2026

[Scientific Reports] To investigate EpCAM, scientists generated stable human MDA-MB-468 breast cancer cell lines with EpCAM knockout, EpCAM overexpression, or mutant unglycosylated EpCAM expression.

GTPBP2 Inactivates Hippo Signaling to Promote Triple-Negative Breast Cancer Cell Malignancy

March 5, 2026

[Scientific Reports] Investigators explored the effects of GTPBP2 on proliferation, migration, and invasion in TNBC, as well as to elucidate its underlying mechanisms.

3D “Emboli” Culture Models Epithelial Breast Cancer Cell Oxidative Mitochondrial Metabolism with Relevance for Lung Metastasis

March 5, 2026

[Cancer Research Communications] Scientists provided a comparative analysis of breast cancer cells in the mammosphere culture model or an “emboli” culture model, which enrich for cancer stem cells and epithelial features, respectively.

Advances in the Study of Pyrotinib for the Treatment of HER2-Positive Breast Cancer

March 5, 2026

[Breast Cancer Research] The authors provide a systematic overview of the pharmacological profile and mechanism of action of pyrotinib, with emphasis on recent clinical trials assessing pyrotinib-based regimens in HER2-positive breast cancer.

SURGE Therapeutics Completes Phase I Dosing of First-in-Category Intraoperative Immunotherapy and Prepares for Registrational Trial

February 18, 2026

[SURGE Therapeutics (Business Wire, Inc.)] SURGE Therapeutics announced the final patient has been dosed in its Phase I clinical trial of SRG-514, an investigational therapy for breast cancer patients undergoing surgery.

PKC-Eta Promotes Breast Cancer Metastasis by Regulating the Hippo-YAP Signaling Pathway

February 18, 2026

[Signal Transduction and Targeted Therapy] Using genetic ablation studies, investigators showed that Protein kinase C-eta (PKCη)- promotes metastasis by enhancing epithelial‒mesenchymal transition and stemness. Notably, compared with those in PKCη-intact tumors, orthotopic xenografts of PKCη-knockout cells in NSG mice resulted in reduced tumor growth and metastasis.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.